The existing literature in IDH wild-type tumors and studies with a mixed cohort of mutant and wild-type patients have reported the incidence rate of PsP is 18% of all patients or 40% of patients with CEnew15–17 which is also similar to our reported PsP incidence of 16% of all patients and 28% of CEnew patients, though it is difficult to compare these values due to the varying definitions of PsP used between studies and use of censored patients. The gene discussed is IDH2; the disease is supranuclear palsy, progressive, 1.